SNSESensei Biotherapeutics Inc
$11.72
$0.93
(8.62%)
Reported EarningsMay 15
Mkt Cap$14.48M
Vol4,675.00
Fundamentals
Mkt Cap
$14.48M
Volume
-
52W High
$36.76
52W Low
$5.60
PE Ratio
-0.56
Avg. Volume
33,751.90
EPS (Annual)
-$16.72
Rev/Employee
$0.00
Earnings
May 15
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on June 1, 2026, the Compensation Committee of Senseis Board of Directors granted three new employees options to purchase an aggregate of 19,300 shares of the Companys common stock in connection with their employment...
Business Wire
Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. The first quarter of 2026 was...
Business Wire
Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company, announced today that the first patient was dosed in Study FTH-PIK-101 (NCT07558733), a Phase 1b/2 trial of PIKTOR...
Business Wire
Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that Company management will present at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16th, 2026 at 12:45 p.m...
Business Wire
Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today reported financial results for the full year ended December 31, 2025, following its previously announced acquisition of Faeth Therapeutics and...
Business Wire
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on March 11, 2026, Senseis Board of Directors granted a new employee an option to purchase 166,435 shares of the Companys...
Business Wire
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on February 19, 2026, Senseis Board of Directors granted 17 new employees, in the aggregate, options to purchase 2,319,893...
Business Wire
Small Cap Stocks To Add to Your Watchlist - February 18th
Rackspace Technology, Direxion Daily PLTR Bear 1X Shares, Spring Valley Acquisition, Direxion Daily MU Bull 2X Shares, Sensei Biotherapeutics, Inflection Point Acquisition Corp. II, and Direxion...
MarketBeat
Sensei Biotherapeutics Stock Soars 230% After Faeth Deal
SNSE up on acquisition of Faeth Therapeutics, $200M private placement, and addition of PIKTOR to pipeline targeting cancer.read more...
Benzinga
<
1
2
...
>
Advertisement|Remove ads.
Latest SNSE News
ViewSensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Business Wire
Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer
Business Wire
Advertisement|Remove ads.